ACADEMIA

Draft of Hypertension Guidelines Recommends CCBs, ARBs, ACE Inhibitors, and Diuretics as First-Line Drugs, Excludes Beta Blockers

August 6, 2013
Calcium channel blockers (CCBs), angiotensin receptor blockers (ARBs), angiotensin converting enzyme (ACE) inhibitors, and diuretics are recommended as first-line drugs in a draft of new hypertension guidelines, which will be compiled by the Japanese Society of Hypertension (JSH) in April…

To read the full story

ACADEMIA

Japan’s health ministry approved a batch of medicines for broader labels on February 9 including Nippon Boehringer Ingelheim’s SGLT2 inhibitor…

By Korkut Bilgin Minoura and Leen Helsloot

The medical affairs domain stands at a pivotal crossroads. In the evolving landscape of medical affairs, what are the challenges,…

By Yoshinori Sagehashi

The pharmaceutical industry seems to appreciate the Japanese government’s FY2024 reform plans for the drug pricing system, but apparently not…

By Izuru Ando

Generic manufacturers in Japan will be required to disclose supply-related information from this June under a new company indicator rule…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

A health ministry panel on pharmaceutical regulations on December 13 discussed the need for confirmatory trial data in Japanese subjects for drugs to treat ultra-rare diseases. The industry proposed waving the implementation of Japanese studies when deemed appropriate in a…

By Yoshinori Sagehashi

The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…

A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…

Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…